about
Expression in Yeast Links Field Polymorphisms in PfATP6 to in Vitro Artemisinin Resistance and Identifies New Inhibitor ClassesPumped up: reflections on PfATP6 as the target for artemisininsPhase 1 Trials of rVSV Ebola Vaccine in Africa and EuropeArtemisinins: their growing importance in medicineThe Plasmodium berghei Ca(2+)/H(+) exchanger, PbCAX, is essential for tolerance to environmental Ca(2+) during sexual developmentStudies with the Plasmodium falciparum hexokinase reveal that PfHT limits the rate of glucose entry into glycolysisA vacuolar iron-transporter homologue acts as a detoxifier in PlasmodiumNew antimalarial targets: the example of glucose transport.Solute transport via the new permeability pathways in Plasmodium falciparum-infected human red blood cells is not consistent with a simple single-channel modelUptake and metabolism of arginine impact Plasmodium development in the liverArtemisone uptake in Plasmodium falciparum-infected erythrocytes.Use of a selective inhibitor to define the chemotherapeutic potential of the plasmodial hexose transporter in different stages of the parasite's life cyclePlasmodial sugar transporters as anti-malarial drug targets and comparisons with other protozoa.Plasmodium falciparum-induced channels.Anionic channels in malaria-infected human red blood cells.The new permeability pathways: targets and selective routes for the development of new antimalarial agents.Mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, enlarge the parasite's food vacuole and alter drug sensitivities.Electrophysiological studies of malaria parasite-infected erythrocytes: current status.Identification, expression and characterisation of a Babesia bovis hexose transporter.Plasmodium berghei-infection induces volume-regulated anion channel-like activity in human hepatoma cellsGLUT1-mediated glucose uptake plays a crucial role during Plasmodium hepatic infection.Exploiting the therapeutic potential of Plasmodium falciparum solute transporters.Susceptibility of human Plasmodium knowlesi infections to anti-malarials.The effect of deoxygenation on whole-cell conductance of red blood cells from healthy individuals and patients with sickle cell disease.Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.Artemether resistance in vitro is linked to mutations in PfATP6 that also interact with mutations in PfMDR1 in travellers returning with Plasmodium falciparum infections.Perturbation of the pump-leak balance for Na(+) and K(+) in malaria-infected erythrocytes.A stretch-activated anion channel is up-regulated by the malaria parasite Plasmodium falciparum.Comparison of effects of green tea catechins on apicomplexan hexose transporters and mammalian orthologues.Artemisinins and the biological basis for the PfATP6/SERCA hypothesis.Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance.Two functionally distinct organic osmolyte pathways in Plasmodium gallinaceum-infected chicken red blood cells.Age-dependent changes in cation transport in the chicken erythrocyte.Furosemide analogues as potent inhibitors of the new permeability pathways of Plasmodium falciparum-infected human erythrocytes.The effect of mefloquine and volume-regulated anion channel inhibitors on induced transport in Plasmodium falciparum-infected human red blood cells.Artemisinin Resistance and the Blame Game.Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis.Modulation of whole-cell currents in Plasmodium falciparum-infected human red blood cells by holding potential and serum.Passive Ca(2+) transport and Ca(2+)-dependent K(+) transport in Plasmodium falciparum-infected red cells.Increased permeability of the malaria-infected erythrocyte to organic cations.
P50
Q22061833-A9963686-F0E6-4AA2-811B-BC741AE4621EQ22061938-91D42EAA-5E76-47F0-ADC8-E1CFC4E84EB8Q24289281-5EDB6895-5465-4E68-95F1-18F14B0E263EQ27489880-091D8C69-8484-4BC2-B297-707E93BEEF0BQ28487202-17E8D6C0-C15D-4A73-9996-90D9F34BB77CQ30041886-8AF70B60-3BB6-4EDA-869C-E3CCEF85C639Q30045593-796EC1B6-B213-4F18-8C3A-5DA7C2CDFD93Q33323960-36FA5828-B738-4053-9CDF-26D7EE40FCE4Q33588539-3D54E82C-2EAB-4DF9-8CD6-C606B6AB00A5Q33826192-98E17337-3D6F-4F45-887E-419E9FF8E5B7Q34529331-91C40184-22AD-4ACE-943F-913F1B881474Q35005159-0808A57B-4D5B-4C1F-AEA6-D977A763ECD1Q35102950-39282BAA-7074-49CE-931B-906503902478Q35757331-601FAD77-8082-40E6-B254-113936E2AB70Q35761918-7DBC2FA7-55D3-4B3F-8C14-365BFC7EE1E4Q36047955-1BC452E2-97DE-4BD2-AC8D-398B0236CCC2Q36106723-67B5E91C-3684-4E72-B569-905C6AA3A136Q36733096-A8348BE5-DA18-4710-9ED6-8E8051597C1DQ37208091-323BB109-F3FA-4DE8-87E2-78BA068861FBQ37414552-82C78D05-EF63-4F0F-B7F7-DE57700329FAQ37631769-D6604E67-9A86-46BA-B690-A76F0F0EE355Q37731112-DADB04E1-E619-471C-ABC4-D6AB3076BF12Q41764422-2028BB94-3E4A-478D-898A-B364CBC56EF7Q41842805-33F32131-8441-4B3D-A3ED-B1461DA32337Q41922839-179641A0-9A58-4B5F-84A1-F1CBD0980189Q42113813-B069DED3-46A6-481B-9007-7E6E589511F7Q42504218-0B190FFF-09D7-42FF-AE06-B767953E2048Q42681789-2A7EF42E-CBF2-4FD7-85F6-8DA4BA980145Q42956408-0750C6EC-E021-4EAE-8EE1-DDA2FD52B0DAQ42967012-5C45416A-3BAD-4ED1-A51C-A9BBC48F3CCEQ43127250-85283A78-C587-4190-B469-FBD618731C61Q43978449-EEBEA591-5EF9-44D4-AD34-1C142718CEE4Q44088189-395739E1-0E34-4FB5-AEDE-3AFB067B458BQ44708389-0C57C444-824F-41C8-B4A6-B1177E49CD2FQ44879124-1D91574E-75B4-431B-9370-CCB60F0248ADQ46673277-3A657F18-D4AB-42B2-AF16-D82E314BB46AQ46705598-EFE061BA-093B-4F01-A992-B091DED38EC8Q47667886-9A7B5D6E-4C40-47AC-B174-D6F1139F85B8Q47855479-B7F7C31B-B295-47FA-9F0A-A7840C6EA520Q47857739-BC829C2A-74D9-4A97-AA9D-4CFE4D51DE84
P50
description
British medical researcher
@en
onderzoeker
@nl
name
Henry Staines
@ast
Henry Staines
@en
Henry Staines
@es
Henry Staines
@nl
Henry Staines
@sl
type
label
Henry Staines
@ast
Henry Staines
@en
Henry Staines
@es
Henry Staines
@nl
Henry Staines
@sl
prefLabel
Henry Staines
@ast
Henry Staines
@en
Henry Staines
@es
Henry Staines
@nl
Henry Staines
@sl
P106
P1153
7004489641
P21
P31
P496
0000-0001-5890-3040